- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03117010
Prospective Cohort for Adult Hemophagocytosis
A Prospective Cohort for Subjects With Adult Hemophagocytic Lymphohistiocytosis Like Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study process is as follows.
- Informed consent for subjects fulfilling the inclusion criteria.
Laboratory evaluation will be done for subjects according to the following diagnostic criteria.
Diagnosis will be established if one of either 1 or 2 below is fulfilled
- A molecular diagnosis consistent with HLH
- Diagnostic criteria for HLH fulfilled (5 out of 8 criteria below)
- fever ≥ 38.5'C for ≥ 7 days
- splenomegaly ≥ 3 finger breadth below left subcostal margin
- cytopenias affecting ≥2 of 3 lineages in peripheral blood (Hemoglobin < 9 g/L, Platelets < 100 × 109/L, Absolute neutrophil count < 1.0 × 109/L)
- Hypertriglyceridemia and/or hypofibrinogenemia: Fasting triglycerides ≥ 265 mg/dL, fibrinogen ≤ 1.5 g/L
- Hemophagocytosis in bone marrow or spleen or lymph node
- Low or absent NK-cell activity (according to local laboratory reference)
- Ferritin ≥ 500 mcg/L
- Soluble CD25 (sIL-2 receptor) ≥ 2,400 U/mL
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Seok Jin Kim, MD, PhD
- Phone Number: +82234101766
- Email: kstwoh@skku.edu
Study Contact Backup
- Name: Silvia Park, MD, PhD
- Phone Number: +82234103459
- Email: silvia.park@samsung.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Recruiting
- Samsung Medical Center
-
Principal Investigator:
- Seok Jin Kim, MD, PhD
-
Sub-Investigator:
- Won Seog Kim, MD, PhD
-
Contact:
- Seok Jin Kim, MD, PhD
- Phone Number: 82-2-3410-1766
- Email: kstwoh@skku.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Subjects should fulfill the following criteria
Subjects should have at least one of the following problems
- Presence of hemophagocytosis in tissue or bone marrow
- Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria
- Age > 18 years
Written informed consents
Exclusion Criteria:
- Subjects cannot satisfy the inclusion criteria
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Hemophagocytosis
Subjects should fulfill the following criteria
Subjects receive steroids and etoposide |
High dose dexamethasone 20 mg PO or IV
Other Names:
Etoposide 150mg/BSA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response
Time Frame: 28 days after the 1st treatment
|
Response to steroids and etoposide
|
28 days after the 1st treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: 3 years
|
Time to date of progression or any kinds of death
|
3 years
|
Overall survival
Time Frame: 3 years
|
Time to date of any kinds of death
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Seok Jin Kim, MD, PhD, Samsung Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Lymphatic Diseases
- Histiocytosis, Non-Langerhans-Cell
- Histiocytosis
- Lymphohistiocytosis, Hemophagocytic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dexamethasone
- Etoposide
Other Study ID Numbers
- 2016-08-117
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophagocytic Lymphohistiocytoses
-
University of California, San FranciscoIncyte CorporationNot yet recruitingRuxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)Hemophagocytic LymphohistiocytosesUnited States
-
Children's Hospital Medical Center, CincinnatiBaylor College of Medicine; Sobi, Inc.RecruitingHemophagocytic LymphohistiocytosesUnited States
-
Swedish Orphan BiovitrumLight Chain Bioscience - Novimmune SATerminatedHemophagocytic LymphohistiocytosesUnited States
-
Swedish Orphan BiovitrumHarvard Medical School (HMS and HSDM); Brigham and Women's HospitalCompletedHemophagocytic LymphohistiocytosesUnited States
-
Beijing Friendship HospitalNot yet recruitingEBV | Hemophagocytic Lymphohistiocytoses | MetabonomicsChina
-
Azienda Ospedaliera Ospedale Infantile Regina Margherita...Completed
-
The Children's Hospital of Zhejiang University...First Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Qilu Hospital... and other collaboratorsRecruitingCytokine Storm | Hemophagocytic LymphohistiocytosesChina
-
Meir Medical CenterRabin Medical Center; Children's Hospital Medical Center, Cincinnati; Sheba Medical... and other collaboratorsRecruitingHematologic Neoplasms | Hematologic Malignancy | Hemophagocytic Syndrome | Hemophagocytic Lymphohistiocytoses | HLHIsrael
-
University of Alabama at BirminghamRecruitingLymphoma | Hemophagocytic LymphohistiocytosesUnited States
-
Beijing Friendship HospitalNot yet recruitingLymphoma | Hemophagocytic LymphohistiocytosesChina
Clinical Trials on Steroids
-
Aier School of Ophthalmology, Central South UniversityUnknown
-
University of California, San DiegoCompletedKnee OsteoarthritisUnited States
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
National Cancer Institute (NCI)CompletedRecurrent High-Grade Gliomas | Malignant Gliomas | Progressive Low-Grade GliomasUnited States
-
Hopital FochCompletedUrinary Bladder Neoplasms | Prostate HyperplasiaFrance
-
Medical University of GrazCompletedColitis, UlcerativeAustria
-
Children's National Research InstituteCompleted
-
All India Institute of Medical Sciences, New DelhiRecruiting
-
Osaka UniversityCompletedMeniere's DiseaseJapan
-
Beni-Suef UniversityCompleted